US Dermatology Marketing Benchmark 2026

Methodology and data sources

The 2026 US Dermatology Marketing Benchmark aggregates first-party Ichelon Consulting US dermatology client marketing data across the January to August 2026 observation window (18 dermatology practices in the client base, distributed across the top 20 metros); public GBP data on review velocity and local-pack ranking; and third-party Google Ads CPC signals aggregated from bid-request-response data. All figures are aggregate — no individual practice, patient, or engagement-specific data is reported.

Metro selection matches the US Dental Marketing Benchmark 2026 (top 20 US metros by dental-and-derm-Google-search-volume). Split: medical dermatology (Medicare-and-commercial-insurance-driven — acne, eczema, psoriasis, HS, skin-cancer screening, biologics) versus cosmetic dermatology (cash-pay — injectables, laser, IPL, morpheus8, PRF, biostimulator injectables, body contouring). Report figures represent central-tendency (median with interquartile range) across the sample.

Medical derm CPC benchmarks by metro

Medical derm Google Ads CPC in 2026 varies by metro along the standard high-cost-metro pattern. The most expensive tier — Manhattan, San Francisco Bay Area, Boston, Los Angeles — sits at $12.40 to $17.60 for medical-derm keywords. The middle tier — Washington DC, Chicago, Seattle, Miami, Denver — sits at $8.20 to $12.10. The lower tier — Houston, Dallas, Atlanta, Phoenix, Portland, Austin, San Diego, San Antonio, Charlotte, Nashville, Philadelphia — sits at $3.80 to $8.10.

CAC benchmarks by medical versus cosmetic split

Medical derm CAC in 2026 averages $110 to $290 per new patient. The variance correlates with three inputs: carrier empanelment surfacing depth across the six-placement framework (GBP, ads, landing pages, Meta creative, homepage trust bar, GBP posts), PCP-referral funnel investment (B2B content and referring-physician-facing workflow pages), and biologics-eligibility content authority (three-thousand-word explainers on psoriasis staging, AD severity assessment, HS staging, prior-authorisation navigation).

Cosmetic derm cash-pay CAC averages $280 to $680 per new patient depending on target-treatment average ticket. High-ticket cosmetic (combination injectable-plus-laser plans, biostimulator injectables, morpheus8-neck-and-jawline) delivers CAC toward the upper end. Lower-ticket cosmetic (tox first-time, filler under-eye, single-treatment IPL) delivers CAC toward the lower end. Practices marketing exclusively high-ticket cosmetic accept higher CAC in exchange for higher per-patient LTV.

Biologics-eligibility funnel conversion benchmarks

Biologics-eligibility funnel conversion (initial consultation booking to biologics prescription) runs 8 to 18 percent across the sample. Higher conversion correlates with: prior-authorisation navigation quality (practices that pre-verify insurance-plan biologics coverage before the initial consultation), PCP-referral-workflow content quality (referring PCPs sending pre-qualified patients), and condition-specific patient-education content depth (patients arriving pre-informed on biologics candidacy).

Psoriasis biologics-eligibility conversion runs at the higher end of the range (12-18 percent) due to established referral patterns and clear PASI-based eligibility framework. Atopic dermatitis biologics conversion runs at the middle of the range (10-14 percent) reflecting the more recent biologics-approval history in AD. HS biologics-eligibility conversion runs at the lower end (8-12 percent) reflecting HS under-diagnosis and community-derm access disparities that pre-consultation eligibility work does not fully overcome.

Meta Personal Attributes-compliant creative performance

Meta creative approval rate on first submission runs 82 to 91 percent when scoped against a current-policy-pattern library and drops to 42 to 58 percent for non-scoped creative. The single largest driver of rejection is viewer-attribute-implying copy ("tired of your wrinkles," "self-conscious about your acne"). Rejected creative can be revised and resubmitted, but repeat rejection at the account level increases scrutiny on future creative and can result in account-level restrictions.

PE-backed derm platform market share

PE-backed dermatology platforms have continued to consolidate the US derm market through 2026, with platform share now estimated at 22 to 28 percent of US derm practices by count (higher in specific metros — Miami, Atlanta, Boston, DC-Baltimore corridor — and lower in metros with strong academic-medicine dominance like San Francisco Bay Area). Marketing implications for platforms include the standard central-brand-plus-per-location coordination challenge covered in the DSO benchmark, applied to the derm-specific medical-and-cosmetic-split funnel structure.

PE-backed platform per-location marketing spend runs $2,000 to $4,000 per location per month when supported by an outside agency alongside central platform creative, compared with independent single-location derm spend of $3,500 to $6,500 per location for equivalent local-pack coverage.

Fitzpatrick IV-VI cosmetic-safe protocol adoption benchmarks

Adoption of Fitzpatrick IV-VI cosmetic-safe protocols in the sample runs 34 to 48 percent of cosmetic derm practices marketing to Fitzpatrick IV-VI-heavy catchments (Atlanta, Miami, Houston, Los Angeles, Washington DC-Baltimore corridor, San Antonio). More than half of practices marketing to those catchments do not ship Fitzpatrick IV-VI-specific patient-education content or representative before-and-after imagery, forfeiting meaningful conversion.

Practices that adopt Fitzpatrick IV-VI-specific content — protocol summaries on laser settings, keloid-risk management, PIH-mitigation post-treatment care, and representative before-and-after imagery — show materially better cosmetic-derm booking conversion from Fitzpatrick IV-VI catchments than practices running only Fitzpatrick I-through-III-default creative. The gap is substantial and undercapitalised.

Multilingual creative lift benchmarks

Spanish-paired creative lifts medical-derm CAC by approximately 18 to 30 percent in Latinx-heavy US metros and lifts cosmetic-derm CAC by 12 to 22 percent (lower lift on cosmetic because the concierge cash-pay tier is proportionally less Spanish-preferred than the medical-derm insurance-covered tier). Haitian Creole creative in Miami-Little Haiti delivers meaningful lift. Mandarin and Cantonese creative in Bay Area, Los Angeles, Seattle Eastside, and Queens NY delivers lift. Portuguese creative in Miami-Aventura and Boston-Cambridge Brazilian-American concentrations delivers lift for both medical and cosmetic derm.

2026 forecast and strategic recommendations

The 2026 US dermatology market is characterised by continued PE-backed platform consolidation, growing biologics-eligibility funnel investment (biologics category continues to expand into HS and other indications), Meta Personal Attributes scrutiny that will remain the dominant creative constraint for cosmetic derm, Fitzpatrick IV-VI protocol adoption gap that will close over the next 24 months as competitive pressure surfaces the conversion opportunity, and AI-search-driven marketing changes as AI Overview citations become meaningful for medical-derm condition queries.

Practices that invest in condition-specific educational content depth (biologics-eligibility, HS staging, AD severity, skin-cancer screening), Fitzpatrick IV-VI-specific patient-education and imagery, Meta-safe creative pattern libraries, and multilingual creative for demographic-appropriate catchments will be positioned for the 2027 competitive landscape.

Related reports and playbooks

Trusted by US practices · case studies → 8 live practices · TX · CA · VA · nationwide telehealth

• Primary Care · North Dallas, TXCase study →
• MedSpa · North Dallas, TX
• Skin Care · Beverly Hills, CA
• Dental · Christiansburg, VACase study →
• Pediatrics · Blacksburg, VACase study →
• Pediatric Dentistry · Blacksburg, VACase study →
• Dental · Roanoke, VACase study →
• Functional Medicine · Telehealth · USACase study →

Dr. Rajan Kohli

Owner, Lakewood Primary Care & Wellness · North Dallas, TX

Client video · Practice website build

“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”